Dashboard
Manage Tickers

BIIB


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-equal-weight-on-biogen-lowers-price-target-to-200
Barclays Maintains Equal-Weight on Biogen,...
04/25/2024 18:02:40

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $215 to $200.

these-analysts-revise-their-forecasts-on-biogen-after-q1-results
These Analysts Revise Their Forecasts On B...
04/25/2024 12:53:14

meta-platforms-to-rally-around-14-here-are-10-top-analyst-forecasts-for-thursday
Meta Platforms To Rally Around 14%? Here A...
04/25/2024 12:44:41

wedbush-maintains-neutral-on-biogen-raises-price-target-to-215
Wedbush Maintains Neutral on Biogen, Raise...
04/25/2024 12:33:01

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $213 to $215.

hc-wainwright--co-maintains-buy-on-biogen-lowers-price-target-to-300
HC Wainwright & Co. Maintains Buy on Bioge...
04/25/2024 11:53:17

HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $325 ...

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
04/25/2024 09:33:02

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

biogeneisais-popular-alzheimers-drug-leqembi-is-seeing-slow-adoption---heres-why
Biogen/Eisai's Popular Alzheimer's Drug Le...
04/24/2024 18:23:08

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and ...

treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-whats-driving-markets-wednesday
Treasury Yields Rise, Tesla Jumps On Cheap...
04/24/2024 17:40:39

Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 3...

biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings
Biogen's Leqembi Commercial Ramp-Up Modest...
04/24/2024 16:12:52

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake t...

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
04/24/2024 12:34:17

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

biogen-reaffirms-2024-adjusted-eps-guidance-of-1500-1600-representing-eps-growth-of-approximately-5-versus-2023-at-the-mid-point-versus-consensus-of-1548
Biogen Reaffirms 2024 Adjusted EPS Guidanc...
04/24/2024 10:53:30

Continue to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expect core pharmaceutical ...

biogen-q1-2024-adj-eps-367-beats-344-estimate-sales-2291b-miss-2311b-estimate
Biogen Q1 2024 Adj EPS $3.67 Beats $3.44 E...
04/24/2024 10:49:10

Biogen (NASDAQ:BIIB) reported quarterly earnings of $3.67 per share which beat the analyst consensus estimate of $3.44 by 6.69 ...

nasdaq-futures-get-a-lift-from-tesla-texas-instruments-earnings-analyst-points-to-key-catalyst-for-boosting-rally
Nasdaq Futures Get A Lift From Tesla, Texa...
04/24/2024 10:37:30

Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ...

can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsoft-meta-alphabet-and-tesla-expected-this-week
Can Magnificent 7 Help Script Market Turna...
04/21/2024 21:45:15

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

oppenheimer-maintains-outperform-on-biogen-lowers-price-target-to-270
Oppenheimer Maintains Outperform on Biogen...
04/19/2024 14:53:00

Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $290 to $270.

wedbush-maintains-neutral-on-biogen-lowers-price-target-to-213
Wedbush Maintains Neutral on Biogen, Lower...
04/17/2024 16:56:02

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $245 to $213.

b-of-a-securities-maintains-neutral-on-biogen-lowers-price-target-to-260
B of A Securities Maintains Neutral on Bio...
04/12/2024 12:00:17

B of A Securities analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $280 ...

where-biogen-stands-with-analysts
Where Biogen Stands With Analysts
04/11/2024 17:01:01

jp-morgan-maintains-neutral-on-biogen-lowers-price-target-to-240
JP Morgan Maintains Neutral on Biogen, Low...
04/11/2024 12:49:29

JP Morgan analyst Chris Schott maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $270 to $240.

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
04/09/2024 17:35:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION